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Abstract 
Slowing of progression and inducing the regression of atherosclerosis with medical therapy 
have been shown to be associated with an extensive reduction in risk of cardiovascular events. 
This proof of concept was obtained with invasive angiographic studies but these are, for 
obvious reasons, impractical for sequential investigations. Non-invasive imaging has henceforth 
replaced the more cumbersome invasive studies and has proven extremely valuable in 
numerous occasions. Because of excellent reproducibility and no radiation exposure, magnetic 
resonance imaging (MRI) has become the non-invasive method of choice to assess the efficacy 
of anti-atherosclerotic drugs. The very high accuracy of this technology is particularly helpful in 
rare diseases where the small number of affected patients makes the conduct of outcome-trials 
in large cohorts impractical.  With MRI it is possible to assess the extent, as well as the 
composition, of atherosclerotic plaques and this further enhances the utility of this technology. 
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Introduction  
Drug discovery and development follow a complex and long pathway that often does not lead 
to a commercially viable product.  As the cost of drug development burgeoned to prohibitive 
levels over the past few decades, investigators and industry have looked for ways to curb 
expenses and increase efficiency minimizing possible failures. The development of new drugs to 
treat atherosclerosis is often met with the requirement to conduct lengthy outcome trials at 
extraordinary costs. To limit the possibility of failing to attain the desired outcome after having 
conducted a phase-3 trial, investigators have utilized surrogate targets that provide information 
on the burden and composition of atherosclerotic plaques.1,2,3 Particularly challenging is the 
development of drugs for rare diseases, where conducting randomized outcome trials is 
hampered by the limited number of patients affected by the condition under study. In this light, 
atherosclerosis imaging has provided intermediate goals to test effectiveness of novel 
treatments.4,5,6 There are indisputable advantages in using imaging endpoints. For example, 
while in mortality and morbidity trials the endpoint is only provided by patients who experience 
an event, in trials based on imaging biomarkers the endpoint is provided by every patient. This 
increases the statistical power of the study, thus leading to a reduction in the number of 
patients compared to event driven trials (tens or hundreds rather than thousands of subjects) 
and shorter follow-ups (6-24 months rather than 4-6 years). Given its potential impact on drug 
development, atherosclerosis imaging has been the focus of intense debate and growing 
interest among scientists, industry and regulators alike. In this paper we review the state of the 
art of magnetic resonance (MR) for vascular imaging, with a specific focus on its 
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implementation in the process of drug development. Magnetic resonance imaging can provide 
information on the location, extent and composition of atheromatous plaques in peripheral 
arterial beds and has been used in numerous trials to study regression of atherosclerosis. 
However, to date MRI has demonstrated no utility to image coronary artery atherosclerotic 
plaques.  
 
Imaging biomarkers and their utility  
Atherosclerosis is mostly a silent disease and autopsy studies revealed that it is already present 
in youth.7 Because of its silent development its first manifestation is often a sudden and 
unheralded event. This induced scientists and physicians to develop a number of algorithms to 
estimate risk of events and stimulated the development of a large array of biomarkers and 
imaging modalities to assess the presence of atherosclerosis and its progression. The earliest 
attempts at measuring atherosclerosis progression were accomplished with invasive coronary 
angiography.8,9,10,11 Several studies demonstrated a powerful reduction in event rates with 
even minimal regression of luminal narrowing with various interventions. 12 Non-invasive 
imaging modalities were then tested to measure change in atherosclerotic plaque burden or 
composition and became rapidly popular as a means to test drug efficacy. Like any other 
biomarker, an imaging marker needs to meet methodological and regulatory requirements to 
provide acceptable outcome parameters.  
Several approaches to biomarker validation have being taken. The NIH Definition Working 
Group13 defines a ‘biomarker’ as follows: 1. A biomarker is a characteristic that is objectively 
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measured and evaluated as an indicator of normal biological processes, pathogenic processes, 
or pharmacological responses to a therapeutic intervention. Boissel and co-workers proposed a 
framework to describe the scientific validity of laboratory parameters for biological outcomes.14 
They posed three stipulations. First [availability and convenience], “although the surrogate 
endpoint should be easier to assess than the corresponding clinical endpoint, the most 
important advantageous characteristic of the biomarker is its potential to detect the disease 
process in its earlier stages, resulting in a higher frequency of detection of the disease than the 
corresponding clinical endpoint”. Consequently, validated biomarkers provide early and specific 
prediction of risk that allow implementation of preventive strategies. For an imaging biomarker 
to provide relevant data, availability of the imaging device in close proximity to study subjects is 
essential. Second, there should be a causal relationship between surrogate and clinical 
endpoint, both quantitatively and qualitatively, through epidemiological studies. Third, it 
should be possible to estimate the clinical benefit derived from a reduction in the incidence of 
the surrogate endpoint. A surrogate outcome must meet certain statistical criteria,15 such that 
it would allow mathematical modeling of a disease process and its consequences.  Finally, to 
become an accepted outcome measure to evaluate efficacy of pharmaceutical products in 
clinical trials, regulatory acceptability must be met.  
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Agencies’ Acceptance of Markers of Disease  
Acceptance of surrogate markers (whether “biomarkers” or others) has long been hotly 
debated and opinions have swayed both in favor and against (some examples are change in 
CD4 cell count in HIV infected patients, change in PSA levels in prostate cancer and blood 
pressure measurements in cardiovascular health).  In many cases there has been deep 
disagreement regarding the relevance of a surrogate endpoint.  Progression free survival in 
oncology is hotly debated and it is not clear if the answer is a simple dichotomous “yes or no” 
but, rather, it might be cancer-specific.  It is likely that surrogacy might also be drug-specific and 
the mechanism of action of one therapy to treat a particular disease might allow one marker as 
a reliable surrogate for drug alone and not another one intended for the same disease state.  
Therefore, regulators have been cautious about declaring any particular marker as an accepted 
surrogate. There are several examples where a compromise had to be reached.  In terms of 
safety, it is often accepted to study “only” a few thousand patients in clinical trials, even though 
we know that databases of this size are unlikely to identify adverse reactions (possibly severe 
reactions) that occur in 1 in 1000 or more patients. Similarly, in terms of efficacy, it is often 
accepted to “only” study treatments for up to 1 – 2 years, even though they might represent 
life-long treatments.  Clearly, these are examples of regulators being pragmatic and recognizing 
that the value of making new therapies available sooner, outweighs the risk involved.  Other 
clear examples of pragmatism are in the orphan drug space where reality often dictates the 
need for flexibility.  Such flexibility may relate to the size of the clinical database presented for 
review (number of patients, duration of follow-up, number of studies, etc.) but also on choice 
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of endpoints.  In terms of size of database, for new products entering Phase III trials from 1 
January 2000, an average of 731 patients were enrolled in orphan drug trials versus 3,540 in 
non-orphan drug trials.16  
Clinical relevance of endpoints is important but so is the ability to study those endpoints in 
small clinical development programmes.  The CHMP (Committee on Medical Products for 
Human Use) Guideline on Clinical Trials in Small Populations (Section 4)17 acknowledges that: 
“Time to disease progression is an endpoint of intermediate level and it requires a measure of 
disease severity or of disease progression. Ideally, this should be validated as a tool for use in 
clinical trials, but it is recognised that there might be too few patients to use some for validating 
endpoints and others for testing treatments. … It is preferable, to be able to identify a causal 
relationship between treatment and a particular (beneficial) outcome.”  Hence the 
acknowledgement that there is an “ideal” and “preferable” way to proceed, but it may not be 
always possible. 
Three questions should be considered; (1) can a study with a “highly preferred” endpoint be 
conducted?  (“highly preferred” might mean preferred by the regulators, and/or an obvious 
clinical endpoint); (2) is such an endpoint absolutely necessary in order to determine the clinical 
value of a therapy? and (3) is it actually desirable to use the “highly preferred” endpoint, or 
would a more efficient trial better serve the public health interest? To this end, intravascular 
ultrasound (IVUS) and MRI studies offer the opportunity to pursue more efficient endpoints (i.e. 
smaller trial sizes, with shorter duration and good level of assurance over the results) than 
more traditional “established clinical endpoints”. At the same time they may provide enough 
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information to inform a decision to pursue larger clinical trials or whether such trials should be 
stopped.18 
Atherosclerosis Imaging for Plaque Regression: a Historical Perspective 
Invasive and non-invasive imaging have been used extensively to study progression of 
atherosclerosis.  A few pivotal principles govern sequential imaging of atherosclerosis to assess 
its temporal changes.1 First, the test-to-test variability should be smaller than the change 
detected with sequential imaging. Second, the measured change should be clinically relevant 
and associated with meaningful outcomes. Atherosclerosis imaging began with quantitative 
invasive coronary angiography (QCA).7-10 Although QCA is not an atherosclerosis imaging 
technique per se, as it assesses the degree of luminal stenosis but not plaque volume and 
composition, it demonstrated that even minimal regression or slowing of progression of 
intraluminal coronary artery disease are associated with a large reduction in event rates.11  
Despite its success, QCA is limited by its invasive nature, the need to use iodinated contrast 
media and the exposure of patients to ionizing radiation and is therefore not fit for population 
studies.  This stimulated and facilitated the development of non-invasive imaging modalities to 
detect atherosclerosis and study its progression. Pignoli et al19 were the first to demonstrate 
that the thickness of the arterial wall comprising the intima and media layers (IMT) of the 
femoral arteries was closely associated with atherosclerosis of the aorta. Given the greater ease 
and convenience of measurement, carotid IMT (cIMT) quickly replaced measurement of 
femoral IMT (Figure 1). Several epidemiological studies later showed that cIMT is an 
independent predictor of stroke and cardiovascular events in the general population.20 As proof 
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of concept, over the last two decades, many investigators have employed cIMT as primary 
endpoint in clinical trials designed to identify populations at risk and assess the effectiveness of 
anti-atherosclerotic drugs.21  
Although successfully employed to study the effect of cardiovascular drugs in large population 
trials, 22,23,24 in several cases randomized clinical trials using the same drugs that regressed cIMT 
gave inconclusive or negative results. cIMT has several distinct disadvantages when used to 
evaluate the efficacy of drugs on regression and progression of atherosclerotic plaques. The 
main limitations of cIMT are the high degree of technical expertise required to perform 
accurate measurements and the high test-to-test measurement variability. As a consequence, 
large numbers of patients are typically needed to demonstrate treatment efficacy due to the 
small arterial wall changes. In addition, cIMT is measured in two-dimensional longitudinal 
images, while atherosclerosis is a three-dimensional, eccentric and irregular disease.  Finally, 
the precision of cIMT measurement may be affected by vessel wall calcification (that causes 
“shadowing”) and the technique does not provide information on plaque composition or risk of 
plaque rupture. It is therefore  virtually impossible to determine whether a change in cIMT 
actually reflects a change in atherosclerosis plaque burden. Modern ultrasound techniques 
measuring plaque volume rather than a mere bi-dimensional IMT have improved the 
reproducibility of carotid atherosclerosis imaging and given a better appreciation of plaque 
volume changes,25,26 but have not been extensively employed for sequential imaging in 
randomized trials. 27,28 
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The high reproducibility of plaque imaging demonstrated by magnetic resonance imaging 
(MRI)29,30 rendered this technique the most advanced and reliable non-invasive tool to conduct 
atherosclerosis imaging. Its low scan-to-scan variability allows investigators to utilize a smaller 
number of patients to demonstrate the efficacy of interventions on plaque size and 
composition.31 These characteristics of high-resolution MRI imaging are particularly desirable 
when research is focused on mechanistic plaque studies of innovative compounds in patients 
with rare diseases who are difficult to discover and enroll in clinical trials.  
As indicated in the previous paragraphs, the value of surrogate biomarkers is embedded in their 
ability to identify a disease state and its change prior to the outbreak of symptomatic disease. 
These properties are crucial when studying rare diseases, as the population size is limited and 
may be geographically widespread. According to the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) group, the average prevalence threshold 
for a rare disease ranges from 5 to 76 cases/100,000 people, with a global average of 40 
cases/100,000 people.32  With such a small prevalence, the inclusion of thousands (or even only 
hundreds) of patients in a study becomes virtually impossible, thus making essential the 
identification of sensitive imaging biomarkers that allow the designing of studies with sufficient 
statistical power despite the availability of only a few dozens of patients.  
 
Magnetic Resonance Imaging in Clinical Trials  
Magnetic Resonance Imaging (MRI) has become one of the leading non-invasive in-vivo imaging 
modalities for quantification and characterization of atherosclerosis. Like ultrasound, MRI does 
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not expose patients to ionizing radiation and can be repeated as often as required: it enables 
measurement of plaque burden (area and volume), luminal narrowing and plaque 
characteristics.33,34 Additionally, with MRI it is possible to assess the thickness of the fibrous-
cap covering a plaque35 and the extent of the lipid-rich necrotic core (LRNC),36 (Figure 2) as well 
as adventitial neovascularization37 and intra-plaque haemorrhage.30 Image acquisition in MRI 
requires a high degree of expertise although most measurements are fairly operator 
independent. Additionally, MRI imaging  provides multi-planar 3D data with sub-millimeter 
spatial resolution.30 Most of the MR vascular imaging work has been performed on 1.5T (Tesla) 
MR scanners. However, more modern imaging at 3T provides a higher signal-to-noise ratio with 
better resolution compared to 1.5T.  The imaging protocols have matured and sequences have 
been optimized enough at 3T that it is recommendable that future clinical studies be conducted 
with 3T scanners.  
The superior reproducibility of MR resulted in the ability to conduct limited size studies to 
demonstrate a proof of concept. In fact, several studies have shown that significant changes in 
carotid atherosclerosis (area or volume) can be detected with moderate sample sizes (less than 
40 patients per arm) within the first months or year of intervention (Table 1 and Figure 3). Lee 
et al,38  observed plaque regression within 3 months of starting statins in 24 treatment naïve 
patients with coronary artery disease. Saam et al39 calculated that a study with only 14 subjects 
per arm is sufficient to assess a 5% treatment effect if the plaque volume is used as an 
endpoint. In a case-control study, eight cases and eight control subjects were sufficient to 
demonstrate that prolonged intensive lipid-lowering therapy is associated with a decrease in 
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lipid-rich necrotic core.40 The power of MRI in showing reduction in atherosclerosis burden in 
rare diseases was clearly demonstrated in two trials employing a new HDL-mimetic drug 
containing recombinant human apoA1 (CER-001). In the MODE trial4 after 12 biweekly infusions 
of CER-001 in 23 patients affected by homozygous familial hypercholesterolemia, MR imaging 
showed a significant reduction in carotid plaque area (P=0.008). Similar results were obtained in 
the SAMBA trial5; in this study of 7 patients affected by familial primary 
hypoalphalipoproteinemia, the mean carotid plaque area was significantly reduced after 9 
biweekly infusions of CER-001 (25 mm2 to 22.8 mm2; P=0.043).  Numerous other trials have 
been conducted to evaluate the efficacy of lipid-lowering therapies and their ability to induce 
atherosclerotic plaque regression as summarized in Table 1. In the first ever trial, Corti et al41 
administered simvastatin to 18 asymptomatic hypercholesterolemic patients with documented 
atherosclerotic plaques in the carotid arteries and/or the aorta. The statin treatment induced 
an 8% regression of the aortic plaque area at 12 months (p<0.001) and the carotid plaque area 
regressed by 15% (p<0.001). Corresponding changes were also seen in vessel wall thickness.  
Subsequent studies assessed the comparative ability of different doses of statins to achieve 
plaque regression and overall showed that the more aggressive the treatment the greater the 
benefit as far as reduction in plaque area or volume. (Table 1)  
 
Atherosclerotic Plaque Imaging With Magnetic Resonance  
Several observational and case-control studies have reported the ability of MRI to identify 
components of the atherosclerotic plaque that might be of interest as goals of therapy. It is 
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however important to note that none of these parameters has been linked with an outcome 
of interest to date. The excellent soft tissue contrast generated from differences in 
relaxation times (T1 and T2) and proton density enables the use of MR imaging to obtain 
detailed information about atherosclerotic plaque composition besides accurate plaque area 
and volume measurements. Histopathological studies have demonstrated that ruptured 
plaques causing acute vascular events are inflamed, contain microcalcifications, a large 
necrotic core, a thin fibrous cap covering the core, intraplaque neo-angiogenesis and 
hemorrhage, and they demonstrate outward (positive) remodeling. Each of these 
characteristics represents a potential imaging target for identifying high-risk plaques with an 
increased risk of rupture.  Many of these plaque characteristics can be accurately identified 
on MR imaging of large vessels.  
 
Necrotic Core. The lipid rich necrotic core can be identified in the carotid arteries and aorta 
using multi-contrast weighted plus post-contrast T1-weighted imaging. In combination these 
techniques can be used to identify and quantify the lipid rich necrotic core burden (LRNC) a 
potentially more sensitive biomarker with which to assess the therapeutic effects of lipid 
lowering therapies. In the ORION trial42 the investigators assessed the effect of rosuvastatin 
on carotid plaque volume and composition. Forty-three patients with hypercholesterolemia 
and carotid plaques were randomized to low (5mg daily) or high (40mg daily) rosuvastatin 
doses. Of interest, at 24 months the plaque volume remained unchanged but there was a 
reduction in the percentage LRNC. 
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Positive Remodeling. The same black-blood imaging technique used to measure plaque 
burden can be used to identify positive remodeling. The presence of positive remodeling of 
the aorta and carotids on MR imaging has been shown to identify patients with an increased 
risk of future cardiovascular events.43  
 
Neovascularization, Plaque Hemorrhage & Luminal Thrombus. Vasa-vasorum proliferate and 
penetrate from the adventitia toward the subintimal space in growing atherosclerotic 
plaques. Since these vessels are particularly fragile they may cause intralesional hemorrhage 
that promotes plaque expansion. 44 Dynamic contrast-enhanced MR imaging allows to 
indirectly estimate the extent of vasa-vasorum proliferation via the calculation of a transfer 
constant: K-trans, i.e the transit of contrast from the adventitia through the vessel wall).45 
Using this technique, Dong et al46 were able to demonstrate that intensive lipid lowering 
therapy for one year induced a 21% reduction in K-trans, suggesting an inhibitory effect on 
vasa-vasorum. 
Methemoglobin is an intermediate breakdown product of hemoglobin formed 12-72 hours 
following haemorrhage. It is therefore a key component of acute thrombus and can be 
detected as regions of high signal on non-contrast T1-weighted echo gradient sequences. 
This has been used to detect both plaque rupture and intra-plaque haemorrhage in the 
carotid arteries. In particular, high signal can be observed in the culprit plaques of patients 
who have suffered a recent stroke.47,48 In a recent study the presence of such high-intensity 
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carotid plaque in stable coronary artery disease patients predicted future cardiovascular 
events, outperforming carotid intimal medial thickness and traditional cardiovascular risk 
factors.49  
 
Late gadolinium enhancement detects regions of extracellular expansion within carotid 
plaques corresponding to areas of inflammation and angiogenesis on histology,30 and 
localizing to the culprit lesions of patients who suffered a stroke. Late gadolinium 
enhancement also allows assessment of the thickness of the fibrous cap in a carotid 
atherosclerotic plaque31 as well as identification of carotid plaque rupture or ulceration that 
may or may not be clinically apparent. 32,33  
Alternative MRI techniques have also been explored as efficacy end-points in clinical trials. 
Ultra-small particles of iron oxide (USPIO) have superparamagnetic properties on T2* 
weighted sequences. They have been used to measure vascular inflammation, since these 
particles are removed from the circulation by the reticuloendothelial system and accumulate 
in macrophages present in atherosclerotic plaques. In the ATHEROMA study 50  the 
investigators randomized 47 patients with carotid stenosis >40% and high USPIO uptake on 
baseline scans, to either 10mg or 80mg of Atorvastatin daily for 12 weeks. A significant 
decrease in the carotid plaque USPIO uptake was observed in the high-dose cohort but not 
the low-dose group.  
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Taken together, these data show that MRI allows an accurate assessment of the effects of 
treatment on atherosclerotic plaque burden and composition with very small sample sizes and 
during short follow-up times. These characteristics make MRI a very efficient tool for a variety 
of clinical trials but especially those involving patients affected by rare diseases for which large 
sample sizes are unavailable. The ability of MRI to detect changes in atherosclerosis burden in 
rare diseases will be tested again in the recently announced TANGO trial  
(https://clinicaltrials.gov/ct2/show/NCT02697136?term=TANGO&rank=6). In this phase III 
multi-center trial, 30 patients with familial primary hypoalphalipoproteinemia on optimal lipid 
lowering medical therapy, will be randomized to treatment with an HDL mimetic compound or 
placebo. The primary end-point of the trial will be change in carotid mean plaque area 
measured by 3T MRI after 24 weeks of treatment. Given the small number of individuals 
recruitable with such a rare disease and the difficulty to assess efficacy, MR appears to be the 
perfect tool to provide the answer to this difficult question.  
 
In summary, in a substantial and growing number of cases the scientific, clinical and 
pharmaceutical communities have embraced non-invasive cardiovascular imaging to evaluate 
changes in human atherosclerosis as a desirable method to assess therapeutic efficacy of novel 
and innovative drugs. Development of pharmaceutical agents designed to slow or prevent 
atherosclerotic disease and improve cardiovascular health can benefit from these imaging 
markers. The available evidence shows that MRI allows an accurate assessment of the effects of 
treatment on atherosclerotic plaque burden and composition with very small sample sizes and 
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short follow-up times. Like cIMT and other imaging modalities, however, to date there have 
been no reports of prospective clinical studies linking MRI-measured atherosclerosis with 
incident clinical events, and these data will need to be actively collected in future trials.  
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Table 1. Effect of lipid modifying drugs on carotid atherosclerosis assessed by magnetic resonance 
imaging  
First 
Author’s 
Name 
Number of 
subjects  
MRI 
parameter 
Study Drug Baseline and 
change in 
LDL (mg/dl) 
Change in MRI 
parameter from 
baseline  
Corti 200137 18 (25 
plaques) 
Vessel wall 
area 
Simvastatin 159+32 
-38% 
-15% (12 months) 
Corti 200251 21 (32 
plaques) 
Vessel wall 
area 
Simvastatin 159+32 
-38% 
-18% (24 months) 
Corti 200552 29 (20mg)                  
22 (80mg) 
Vessel wall 
area 
Simvastatin 
20mg 
Simvastatin 
80mg 
154+31 and 
173+33 
-26% and  
-46% 
-14% (12months)                       
-18% (24months) 
Yonemura 
200553 
21 (5mg)                      
19 (20mg) 
Vessel wall 
area 
Atorvastatin 
5mg         
Atorvastatin 
20mg 
200+30 and 
201+46 
-34% and 
-47% 
+4±16% (5mg 12 
months)          
 -18±10% (20mg, 12 
months) 
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Lee JM 
200854 
24 Normalized 
wall index 
(wall 
area/total 
area) 
Simvastatin 
40mg (n=15)              
Simvastatin 10-
20mg (n=5)    
Atorvastatin 
(n=4) 
Overall 
mean 
baseline 
112+39 
-29% 
-7%  
(12 months) 
Underhill 
200838 
18 with 
LRNC 
Lipid-Rich 
Necrotic 
Core  
Rosuvastatin 
5mg              
Rosuvastatin 
40mg 
148+27 and 
153+31 
-38% and 
-60% 
-41%  
(24 months) 
Tang 200943 47 USPIO 
uptake on 
T2* 
imaging 
Atorvastatin 
10mg                  
Atorvastatin 
80mg 
88 and 97 
+5% and  
-22% 
-6.2%  
(12 weeks) 
Zhao 201155 33 with 
LRNC 
Lipid-Rich 
Necrotic 
Core 
Atorvastatin ± 
covesevelam + 
niacin 
148+29 
-52% 
-38%  
(36 months) 
Sibley 
201356 
73 Carotid 
Wall 
Multiple 
statin doses 
171 -6%  
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Volume + niacin -11% (18 months) 
Hovingh 
20154 
23 with FH Vessel wall 
area 
CER-001 214+81 
N/A 
-2.5%  
(6 months)  
Kootte 
20155 
7 with 
FPHA 
Vessel wall 
area 
CER-001 77+54 
N/A 
-8.8%  
(18 weeks) 
 
Legend: CER-001: recombinant human apolipoprotein A-1 containing HDL-mimetic particle 
FH: familial hypercholesterolemia. FPHA: familial primary hypoalphalipoproteinemia. LDL: low density 
lipoprotein. LRNC: lipid rich necrotic core. USPIO: ultra-small particles of iron oxide. N/A: not available  
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Figure legends 
 
Figure 1: Longitudinal bi-dimensional image of the right common carotid artery showing a very 
thick intima-media layer of the far wall (solid arrows) and mild thickening of the near wall 
(arrow phantoms).  
 
Figure 2: Cross sectional high-resolution black blood image of the left carotid bulb showing a 
lipid rich atheromatous plaque with a thick fibrous cap. The inset shows an enlargement of the 
plaque encircled by the broken line. The lipid core is indicated by the white arrow (courtesy of 
Dr. Richard Coulden, Department of Diagnostic Imaging, University of Alberta, AB, Canada). 
 
Figure 3: Cross sectional high-resolution black blood image of the left internal carotid artery at 
baseline (A) and after 6 months (B) showing increase in wall thickness at follow-up (white 
arrows point to the thickened carotid wall). 
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